Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma.
Liu, H., Niu, D., Tham Sjin, R.T., Dubrovskiy, A., Zhu, Z., McDonald, J.J., Fahnoe, K., Wang, Z., Munson, M., Scholte, A., Barrague, M., Fitzgerald, M., Liu, J., Kothe, M., Sun, F., Murtie, J., Ge, J., Rocnik, J., Harvey, D., Ospina, B., Perron, K., Zheng, G., Shehu, E., D'Agostino, L.A.(2020) ACS Med Chem Lett 11: 1899-1904
- PubMed: 33062171 
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00601
- Primary Citation of Related Structures:  
6V9C - PubMed Abstract: 
Hepatocellular carcinoma (HCC) accounts for a majority of primary liver cancer and is one of the most common forms of cancer worldwide. Aberrant signaling of the FGF19-FGFR4 pathway leads to HCC in mice and is hypothesized to be a driver in FGF19 amplified HCC in humans ...